Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)

Trial Profile

Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)

Phase of Trial: Phase I

Latest Information Update: 09 May 2019

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Cerebrovascular disorders; Venous thromboembolism
  • Focus Pharmacokinetics
  • Acronyms RivaMoS-2
  • Most Recent Events

    • 31 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Oct 2014 Planned End Date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 08 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top